West Pharmaceutical Services, Inc.
NYSEWST cost to borrow doubles to 0.39% in one week, rising from 0.18% as borrow scarcity tightens despite low short interest at 3.1% of float.
West Pharmaceutical Services has attracted a notable analyst upgrade this week. The signals are pointing in the same direction. Morgan Stanley upgraded WST to Overweight on September 22, raising its price target to…
West Pharmaceutical Services heads into its July 30 report already carrying the bruise from last week's earnings-day drop — and the setup has shifted materially since the previous preview. The stock fell 8.4% on July…
Snapshot as of 4 Oct 2026
West Pharmaceutical Services approaches its July 23 earnings print with the strongest wall of analyst conviction it has seen in months — and a stock that has finally started to catch up. The analyst story is the…
Options positioning for WST has flipped sharply in less than a week. Short sellers are also retreating. The signals point the same direction. On May 15, the put/call ratio hit 2.25 — the highest in two months. Five…
West Pharmaceutical Services enters its May 4 Q1 2026 earnings call having staged a remarkable comeback — up 21% over the past month to $297.59 — yet peers in the life sciences tools space spent last week in…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for WST — free to start on ORTEX.
Sign up for free →Open WST on ORTEX